Compare ADMA Biologics Inc (ADMA) vs Modine Manufacturing Company (MOD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Modine Manufacturing Company — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while Modine Manufacturing Company trades at $226.59 (market cap $12.17B). The key difference: Modine Manufacturing Company is far larger — about 5.7× ADMA Biologics Inc's market cap, and Modine Manufacturing Company is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | MOD | |
|---|---|---|
Market Cap | $2.13B | $12.17B |
Sector | Health | Technology |
52-Week High | $20.38 | $306.89 |
52-Week Low | $7.60 | $90.02 |
Enterprise Value | $2.20B | $12.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Modine (MOD) trades at $235.19, up 1.83% on the day, amid a bearish technical signal despite recent earnings beats. The company reported strong revenue growth to $2.58B in 2025, with net income of $184M, though 2026 projections show margin compression. Analyst consensus remains strongly bullish with a $328.80 price target, driven by optimism around its data center cooling business, which is expected to grow 60-80% in FY27 according to Seeking Alpha (2026-06-11).
The outlook is mixed: robust growth in data center demand offers significant upside, but high valuations (P/E 104.07) and near-term technical weakness pose risks. Investors face volatility from supply chain challenges and competitive pressures in the HVAC segment, though institutional support and consistent earnings outperformance provide a foundation for long-term growth if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →
